Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway

The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaccour, Carlos, Rabinovich, N. Regina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402168/
https://www.ncbi.nlm.nih.gov/pubmed/28434405
http://dx.doi.org/10.1186/s12936-017-1802-3
_version_ 1783231173702451200
author Chaccour, Carlos
Rabinovich, N. Regina
author_facet Chaccour, Carlos
Rabinovich, N. Regina
author_sort Chaccour, Carlos
collection PubMed
description The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.
format Online
Article
Text
id pubmed-5402168
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54021682017-04-24 Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway Chaccour, Carlos Rabinovich, N. Regina Malar J Review The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested. BioMed Central 2017-04-24 /pmc/articles/PMC5402168/ /pubmed/28434405 http://dx.doi.org/10.1186/s12936-017-1802-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Chaccour, Carlos
Rabinovich, N. Regina
Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
title Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
title_full Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
title_fullStr Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
title_full_unstemmed Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
title_short Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
title_sort ivermectin to reduce malaria transmission ii. considerations regarding clinical development pathway
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402168/
https://www.ncbi.nlm.nih.gov/pubmed/28434405
http://dx.doi.org/10.1186/s12936-017-1802-3
work_keys_str_mv AT chaccourcarlos ivermectintoreducemalariatransmissioniiconsiderationsregardingclinicaldevelopmentpathway
AT rabinovichnregina ivermectintoreducemalariatransmissioniiconsiderationsregardingclinicaldevelopmentpathway

Ejemplares similares